Analyst consensus rating
BioNTech Analyst Rating: Buy
Direct answer
BioNTech's consensus rating is Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $116.70.
Forecast evidence checked October 24, 2026.
Get free BioNTech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $88.12
- Average price target
- $116.70
- High price target
- $144.08
- Low price target
- $76.04
- Low target gap
- -13.7%
- Target upside
- +32.4%
- High target gap
- +63.5%
- Target range width
- 77.2%
- Consensus rating
- Buy
- Analysts
- 20
- Evidence date
- October 24, 2026
- Valid through
- October 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BioNTech?
BioNTech has a verified Buy consensus. The same dataset has an average price target of $116.70.
How far are BioNTech's low and high targets from the recorded price?
The low target implies -13.7%, while the high target implies +63.5%.
How many analysts are included in BioNTech's consensus?
The verified consensus includes 20 analysts.
How is BioNTech's target upside or downside calculated?
The average target of $116.70 is divided by the recorded price of $88.12, then one is subtracted to produce +32.4%. This does not guarantee a future return.
When was BioNTech's analyst forecast verified?
The data was verified on 2026-10-24. The dataset is valid through 2026-10-31.